

## **China Antibody Drug Conjugates Contract Manufacturing Market Forecast 2024-2032**

Market Report | 2024-05-20 | 121 pages | Inkwood Research

### **AVAILABLE LICENSES:**

- Single User Price \$1100.00
- Global Site License \$1500.00

### **Report description:**

#### **KEY FINDINGS**

The China antibody drug conjugates contract manufacturing market is expected to progress at a CAGR of 12.34% during the forecast period 2024-2032. Diverse enablers foster market growth, the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.

#### **MARKET INSIGHTS**

The China antibody drug conjugates contract manufacturing market is a vital segment of the country's pharmaceutical industry. With the rising incidence of cancer globally, there is an increasing demand for effective treatment options such as antibody drug conjugates. This demand has fueled the growth of contract manufacturing organizations (CMOs) specializing in ADC production, catering to both domestic and international pharmaceutical companies.

One of the key factors driving this market is the advancements in drug conjugation technologies. These technologies have enabled the development of more targeted and efficient ADCs, improving their efficacy and safety profiles. As a result, pharmaceutical companies are increasingly outsourcing ADC manufacturing to specialized CMOs in China, leveraging their expertise in this niche field.

Furthermore, collaborations between key players in the China ADC contract manufacturing market and global pharmaceutical firms have become more prevalent. These collaborations harness scientific knowledge, manufacturing capabilities, and regulatory expertise. They facilitate seamless production and delivery of high-quality ADCs, meeting the increasing demand for innovative cancer therapies in China and globally.

#### **COMPETITIVE INSIGHTS**

Some of the major companies in the China antibody drug conjugates contract manufacturing market include AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Lonza Group, etc.

Our report offerings include:

- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation caters to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- The competitive landscape is the theoretical explanation of the key companies based on factors such as market share.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

## **Table of Contents:**

### TABLE OF CONTENTS

#### 1. RESEARCH SCOPE & METHODOLOGY

##### 1.1. STUDY OBJECTIVES

##### 1.2. METHODOLOGY

##### 1.3. ASSUMPTIONS & LIMITATIONS

#### 2. EXECUTIVE SUMMARY

##### 2.1. MARKET SIZE & ESTIMATES

##### 2.2. COUNTRY SNAPSHOT

##### 2.3. COUNTRY ANALYSIS

##### 2.4. SCOPE OF STUDY

##### 2.5. CRISIS SCENARIO ANALYSIS

##### 2.6. MAJOR MARKET FINDINGS

##### 2.6.1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)

##### 2.6.2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS

#### 3. MARKET DYNAMICS

##### 3.1. KEY DRIVERS

##### 3.1.1. RISING DEMAND FOR TARGETED THERAPIES

##### 3.1.2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE

##### 3.1.3. SURGING GLOBAL CANCER INCIDENCE

##### 3.1.4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES

##### 3.2. KEY RESTRAINTS

##### 3.2.1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING

##### 3.2.2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS

##### 3.2.3. STRINGENT REGULATORY REQUIREMENTS

#### 4. KEY ANALYTICS

##### 4.1. KEY MARKET TRENDS

##### 4.1.1. RISING DEMAND FOR ADCS

##### 4.1.2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE

##### 4.2. PESTLE ANALYSIS

##### 4.2.1. POLITICAL

##### 4.2.2. ECONOMICAL

##### 4.2.3. SOCIAL

##### 4.2.4. TECHNOLOGICAL

##### 4.2.5. LEGAL

##### 4.2.6. ENVIRONMENTAL

##### 4.3. PORTER'S FIVE FORCES ANALYSIS

##### 4.3.1. BUYERS POWER

##### 4.3.2. SUPPLIERS POWER

##### 4.3.3. SUBSTITUTION

##### 4.3.4. NEW ENTRANTS

##### 4.3.5. INDUSTRY RIVALRY

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.4. GROWTH PROSPECT MAPPING
  - 4.4.1. GROWTH PROSPECT MAPPING FOR CHINA
- 4.5. MARKET CONCENTRATION ANALYSIS
- 4.6. KEY BUYING CRITERIA
  - 4.6.1. EXPERTISE AND EXPERIENCE
  - 4.6.2. MANUFACTURING CAPACITY
  - 4.6.3. REGULATORY COMPLIANCE
  - 4.6.4. QUALITY CONTROL
  - 4.6.5. COST
- 4.7. REGULATORY FRAMEWORK
- 5. MARKET BY PHASE
  - 5.1. CLINICAL PHASE
    - 5.1.1. MARKET FORECAST FIGURE
    - 5.1.2. SEGMENT ANALYSIS
  - 5.2. COMMERCIAL PHASE
    - 5.2.1. MARKET FORECAST FIGURE
    - 5.2.2. SEGMENT ANALYSIS
- 6. MARKET BY LINKER
  - 6.1. CLEAVABLE LINKERS
    - 6.1.1. MARKET FORECAST FIGURE
    - 6.1.2. SEGMENT ANALYSIS
  - 6.2. NON-CLEAVABLE LINKERS
    - 6.2.1. MARKET FORECAST FIGURE
    - 6.2.2. SEGMENT ANALYSIS
- 7. MARKET BY CONDITION
  - 7.1. MYELOMA
    - 7.1.1. MARKET FORECAST FIGURE
    - 7.1.2. SEGMENT ANALYSIS
  - 7.2. LYMPHOMA
    - 7.2.1. MARKET FORECAST FIGURE
    - 7.2.2. SEGMENT ANALYSIS
  - 7.3. BREAST CANCER
    - 7.3.1. MARKET FORECAST FIGURE
    - 7.3.2. SEGMENT ANALYSIS
  - 7.4. OTHER CONDITIONS
    - 7.4.1. MARKET FORECAST FIGURE
    - 7.4.2. SEGMENT ANALYSIS
- 8. COMPETITIVE LANDSCAPE
  - 8.1. KEY STRATEGIC DEVELOPMENTS
    - 8.1.1. MERGERS & ACQUISITIONS
    - 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    - 8.1.3. PARTNERSHIPS & AGREEMENTS
  - 8.2. COMPANY PROFILES
    - 8.2.1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
      - 8.2.1.1. COMPANY OVERVIEW
      - 8.2.1.2. SERVICES LIST
      - 8.2.1.3. STRENGTHS & CHALLENGES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.2.2. LONZA GROUP
  - 8.2.2.1. COMPANY OVERVIEW
  - 8.2.2.2. SERVICES LIST
  - 8.2.2.3. STRENGTHS & CHALLENGES
- 8.2.3. MERCK KGAA
  - 8.2.3.1. COMPANY OVERVIEW
  - 8.2.3.2. SERVICES LIST
  - 8.2.3.3. STRENGTHS & CHALLENGES
- 8.2.4. SAMSUNG BIOLOGICS
  - 8.2.4.1. COMPANY OVERVIEW
  - 8.2.4.2. SERVICES LIST
  - 8.2.4.3. STRENGTHS & CHALLENGES
- 8.2.5. WUXI BIOLOGICS
  - 8.2.5.1. COMPANY OVERVIEW
  - 8.2.5.2. SERVICES LIST
  - 8.2.5.3. STRENGTHS & CHALLENGES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## China Antibody Drug Conjugates Contract Manufacturing Market Forecast 2024-2032

Market Report | 2024-05-20 | 121 pages | Inkwood Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)

### ORDER FORM:

Select license	License	Price
	Single User Price	\$1100.00
	Global Site License	\$1500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact [support@scotts-international.com](mailto:support@scotts-international.com) or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)